Navigation Links
Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/14/2009

pproximately $4.47 million, compared to approximately $6.39 million for the same period in 2008. The $1.92 million decrease is primarily attributable to lower Intermezzo(R) development costs, the majority of which were incurred prior to the submission of the Intermezzo(R) NDA on September 30, 2008. Research and development expenses included non-cash stock compensation expense in accordance with SFAS No. 123R of approximately $157,000 for the six months ended June 30, 2009 and $130,000 for the six months ended June 30, 2008.

General and administrative expenses for the six months ended June 30, 2009 were approximately $9.23 million, compared to approximately $3.22 million for the same period in 2008. The $6.01 million increase consists primarily of higher professional fees to operate as a public company and to negotiate our collaboration with Purdue, increased personnel costs primarily in marketing and administration, increased marketing expenses as we prepared to commercialize Intermezzo(R) and an increase in operational expenses associated with the addition of the Novacea office space in South San Francisco.

General and administrative expenses included non-cash stock compensation expense in accordance with SFAS No. 123R of approximately $394,000 for the six months ended June 30, 2009, as compared to $162,000 for the six months ended June 30, 2008.

Year-to-date merger-related transaction costs of approximately $2.22 million were expensed during the first quarter of 2009.

Net loss for the six months ended June 30, 2009 was approximately $15.7 million or $1.42 per share, compared to a net loss of approximately $9.6 million or $26.16 per share for the six months ended June 30, 2008. The weighted average common shares used to calculate earnings per share were 11,047,881 and 366,226 respectively for the six months ended June 30, 2009 and 2008.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Transcept Pharmaceuticals to Report Second Quarter 2009 Results
2. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
3. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
4. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
5. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
6. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
7. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
8. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
9. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
10. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
11. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014 M3 Global Research , ... professional panel, today announced two important leadership changes to help ... as President of Market Research, Americas and the promotion of ... , Ms. DasGupta joined M3 in 2011 and has ... Head of Sales. Roni has over 17 years of ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, ... pregnant are much more likely to have a child who ... But it looks like environment may play a greater ... "Mothers who are overweight teach behaviors, and those behaviors are ... a research fellow at the Framingham Heart Study, Boston University ...
(Date:11/21/2014)... (HealthDay News) -- Some people with cochlear implants experience ... when they undergo an MRI scan, a new study ... researchers, about 300,000 people worldwide have cochlear implants, devices ... are deaf or have severe hearing loss. There have ... implants when undergoing MRI. One expert said the ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 (HealthDay ... rules that will make it easier for everyone to know ... The proposed changes would expand the number of trials that ... -- a publicly accessible database, according to the U.S. National ... and Human Services. "This proposed rule would close ...
(Date:11/21/2014)... THURSDAY, Nov. 20, 2014 (HealthDay News) -- Kidney donation ... do for another. And now a new study finds that ... life are benefiting from policies that give them priority on ... almost 6,300 of the 16,900 kidney transplants that took place ... supplied by the study researchers. At the time ...
Breaking Medicine News(10 mins):Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2Health News:Kids Born to Overweight Moms May Face Higher Heart Risks as Adults 2Health News:MRI Can Be Painful, Disruptive for People With Cochlear Implants 2Health News:U.S. Proposes Greater Public Access to Data From Clinical Trials 2Health News:Study Supports Giving Kidney Donors Priority When They Need a Kidney 2
... June 24 Antibiotic resistance is one,of the ... and the focus of,today,s Senate hearing, Emergence of ... pose a threat to US healthcare,s reliance,on high ... for adversaries to exploit in building biological weapons., ...
... 24 The American Lung,Association commends and thanks ... the Pulmonary and Cardiac Rehabilitation Act today. As ... Providers Act of,2008, the Pulmonary and Cardiac Rehabilitation ... easier for millions of Americans who suffer from,serious ...
... Herrup and colleagues at Case Western Reserve University have ... brain cells effectively "puts the brakes" on the dementia ... fail, dementia results. , This discovery could open the ... affects up to half the population over the age ...
... leading provider of health and,human services for government ... the Iowa Department of Human Services (DHS) to ... in Iowa (hawk-i),Program. As part of Iowa,s State ... health insurance coverage for,uninsured children in Iowa whose ...
... Framework for Decision Making on ... State Retiree Health Care Benefits, WASHINGTON, June 24 ... Excellence looks at the complexities surrounding,the funding of state retiree ... Dollars and Health Sense: A Framework for Decision Making on,Funding ...
... "Heart disease,the main killer in the United States, ... largely treatable through diet, exercise and early,detection," an organization ... men and women die of cardiovascular disease each year ... can be elusive and patients may,have had no prior ...
Cached Medicine News:Health News:Federal Action Needed to Fill Antibiotic Pipeline, Says the Alliance for the Prudent Use of Antibiotics 2Health News:American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act 2Health News:Alzheimer's disease as a case of brake failure? 2Health News:Iowa Awards Policy Studies Inc. (PSI) Contract to Operate Its hawk-i Children's Health Insurance Program 2Health News:Balancing Dollars and Health Sense 2Health News:Concerns About Heart Disease Voiced 2
(Date:11/21/2014)... YORK , Nov. 20, 2014  Market research firm ... the "Year of The Buy, in the medical device ... for medical devices will produce just 3% growth this ... actions, including acquisitions of product lines and entrance by ... annual survey of medical devices, The Global Market ...
(Date:11/21/2014)... SUNNYVALE, Calif. , Nov. 20, 2014 /PRNewswire/ ... Study at the 2014 AAGL Global Congress demonstrates ... vaginal insert designed to provide bowel control. One of ... MD, Associate Professor and Division Chief of Urogynecology ... North Carolina, won an Award for Best Written ...
(Date:11/21/2014)... BEVERLY HILLS, Calif. , Nov. 20, 2014 ... Ken Eaton , the election of Anthony J. ... as President. Effective November 19, 2014, ... and member of the Board of Directors of Oxis International, ... J. Cataldo has been named Chief Executive Officer of ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 2LIFE Study Prominently Featured at Minimally Invasive Gynecology Conference 3OXIS International, Inc. announces Changes in Management Team 2OXIS International, Inc. announces Changes in Management Team 3
... The Anti-HCV Low Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by manufacturers and ... Comprehensive data from all major test systems ...
... The Anti-HCV Mixed Titer Performance Panel ... from weak to strong positive for antibodies ... is intended for use by diagnostic manufacturers ... and RNA assays. Comprehensive data from all ...
... POPmesh is a ... that can be used ... pelvic floor procedures, including ... prolapse. Supple yet strong, ...
Suspend® Tutoplast® Processed Fascia Lata is your naturally safe and strong choice for pelvic floor reconstruction. Suspend comes from a dense matrix of collagen bundles and transverse fasc...
Medicine Products: